Patents by Inventor Pascal Barneoud

Pascal Barneoud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • H3 receptor antagonist for use in the treatment of alzheimer's disease
    Patent number: 9789102
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 17, 2017
    Assignee: SANOFI
    Inventors: Pascal Barneoud, Veronique Blanchard-Bregeon, Veronique Mary, Jean Menager, Philippe Delay-Goyet, Mathilde Lopez-Grancha, Thomas Rooney, Nathalie Schussler
  • H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20160256449
    Abstract: The disclosure relates to the compound 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof, intended for the treatment of Alzheimer's disease and other types of dementia.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 8, 2016
    Inventors: Sophie CLAUDEL, Jeanne STEMMELIN, Pascal BARNEOUD, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Jeremy PRATT
  • H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20160101099
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Application
    Filed: October 1, 2015
    Publication date: April 14, 2016
    Inventors: Pascal BARNEOUD, Veronique BLANCHARD-BREGEON, Veronique MARY, Jean MENAGER, Philippe DELAY-GOYET, Mathilde LOPEZ-GRANCHA, Thomas ROONEY, Nathalie SCHUSSLER
  • AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20150031893
    Abstract: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Inventors: Pascal BARNEOUD, Veronique BLANCHARD-BREGEON, Veronique MARY, Jean MENAGER, Philippe DELAY-GOYET, Mathilde LOPEZ GRANCHA, Thomas ROONEY, Nathalie SCHUSSLER
  • 6-pyrimidinyl-pyrimid-4-one derivative
    Patent number: 8518939
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: August 27, 2013
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE
    Publication number: 20120252812
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Application
    Filed: May 9, 2012
    Publication date: October 4, 2012
    Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kenji FUKUNAGA, Kazutoshi WATANABE, Pascal BARNEOUD, Jesus BENAVIDES, Jeremy PRATT
  • 6-pyrimidinyl-pyrimid-4-one derivative
    Patent number: 8198437
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: June 12, 2012
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi-Aventis
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE
    Publication number: 20110021773
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Application
    Filed: September 12, 2008
    Publication date: January 27, 2011
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SANOFI-AVENTIS
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
    Publication number: 20040224409
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for brain-derived neurotrophic factor (BDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 11, 2004
    Inventors: Laurent Pradier, Pascal Barneoud, Pia Delaere, Michel Perricaudet, Emmanuelle Vigne